This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dyax Corp. (DYAX)
Deutsche Bank AG Health Care Conference Call
May 7, 2012 9:20 am ET
Gustav A. Christensen – President and Chief Executive Officer
Robyn Karnauskas – Deutsche Bank Securities
PresentationRobyn Karnauskas – Deutsche Bank Securities
Good morning. My name is Robyn Karnauskas, I am the Deutsche Bank Biotech analyst. Next we have Dyax Corporation, speaking for Dyax is Gustav Christensen, President and CEO. And for those of you who are listening through the webcast, do you have any questions you can email me at firstname.lastname@example.org or we have a new way to access the conference and ask questions synonymously at yorn.com/hc and we can see your questions without knowing who you are. Questions or comments we'll read towards the end.
With that, I’ll turn it over to Gustav.
Gustav A. Christensen
Thank you very much Robyn. I want to thank Deutsche Bank for having us back again at this Annual Healthcare Conference, it’s always a pleasure. I want to thank you for sitting in on the Dyax presentation this morning, I’m looking forward to update you on Dyax and tell you why we are excited about Dyax and it’s future and it’s value proposition.
So it is a presentation in which I will be making some forward-looking statements and therefore call your attention to the Safe Harbor statement.
So Dyax is today a fully integrated biopharmaceutical company, while there are few who have made that for. We have done so by developing and evolving our phage technology phage display, a technology that not only Dyax have utilized to discover up our own products. But build a solid licensing business where other people are using the product and have developed a large pipeline. So where Dyax we have discovered developed and are now selling our first pharmaceutical product KALBITOR for hereditary angioedema attacks. We’re working on phase II studies to expand the label, the first one in ACE inhibitor-induced angioedema they met a medical problem.